Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2023-11-02 Regulatory Filings
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Cardiff Oncology, Inc. It announces the release of third quarter 2023 financial results and a related earnings conference call with presentation materials. The text references a press release and an earnings call presentation as exhibits, but the document itself is a regulatory filing reporting these events. The length is 4156 characters, which is relatively short and consistent with a Form 8-K announcement rather than a full earnings release or detailed financial report. The document does not contain the actual financial statements or detailed financial data but rather announces the results and the call. Therefore, this is best classified as a Regulatory Filing (RNS) since it is a current report announcing events and filings rather than the earnings release itself or the call transcript.
2023-11-02 English
10-Q
Interim / Quarterly Report 9M 2023
2023-11-02 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 26, 2023. It includes a corporate presentation (Exhibit 99.1) and a press release (Exhibit 99.2) announcing clinical data and plans for trials. The document is short (3980 characters) and primarily serves to announce and furnish information rather than provide detailed financial data or full reports. The presence of a corporate slide presentation and press release indicates this is an update or announcement rather than a full financial report or earnings release. According to the classification rules, such filings that provide presentations and updates to investors without full financial statements or detailed analysis are best classified as Investor Presentation (IP).
2023-09-26 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 8, 2023. It includes announcements of financial results for the second quarter ended June 30, 2023, but the financial results are provided via a press release attached as Exhibit 99.1, not detailed in the document itself. Additionally, it reports an amendment to the company's articles of incorporation regarding elimination of certain preferred stock series. The document is primarily an announcement of events and filings rather than a full financial report. The presence of a press release announcing quarterly financial results aligns with an Earnings Release (ER) filing type. The document is about current events and financial highlights, not a full interim report with detailed financial statements. Therefore, the best classification is Earnings Release (ER).
2023-08-09 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a Regulation FD Disclosure about a corporate slide presentation and a press release about advancing a clinical trial program. The document is short (4327 characters) and primarily announces the availability of a presentation and a press release, rather than containing detailed financial data or the presentation itself. According to the 'Menu vs Meal' rule, such a document is an announcement of materials rather than the materials themselves. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-08-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.